Guideline Perspectives on Cardiometabolic Residual Risk Management

Abstract

Cardiometabolic residual risk persists in patients despite optimal management of traditional risk factors such as low-density lipoprotein cholesterol (LDL-C), hypertension, and glycemic control. This review synthesizes current guideline perspectives, recent clinical evidence, and emerging therapies aimed at addressing residual risk in cardiometabolic disease. Emphasis is placed on updated epidemiology, mechanisms underlying residual risk, and practical clinical strategies, including the role of novel agents and comprehensive risk stratification. Insights into the integration of recent advances within existing guideline frameworks offer a practical blueprint for clinicians managing high-risk populations.

Introduction

Despite substantial progress in the prevention and management of atherosclerotic cardiovascular disease (ASCVD) and diabetes, a significant burden of residual risk remains. Traditional interventions targeting LDL-C, blood pressure, and glycemic control have reduced cardiovascular events, yet many patients continue to experience major adverse cardiovascular events (MACE). Understanding and managing this residual risk has become a central focus in contemporary cardiometabolic care. This article provides an updated review of guideline-driven approaches to residual risk, integrating recent scientific advances and their clinical implications.

Epidemiology / Disease Burden

Cardiometabolic diseases are the leading cause of global mortality, accounting for over 17 million deaths annually. While statin therapy and antihypertensive regimens have decreased cardiovascular event rates, registry and cohort studies consistently demonstrate a persistent risk, with up to 50% of events occurring despite achieving guideline-recommended targets. This residual risk is particularly notable in populations with diabetes, metabolic syndrome, chronic kidney disease, and established ASCVD. The prevalence of obesity, insulin resistance, and non-alcoholic fatty liver disease further compounds the epidemiological challenge, underscoring the need for strategies beyond conventional risk factor management.

Pathophysiology

Residual cardiometabolic risk is multifactorial, extending beyond traditional pathways. While LDL-C reduction is foundational, non-LDL lipoproteins—including triglyceride-rich lipoproteins (TRLs) and lipoprotein(a)—contribute significantly to atherogenesis. Persistent inflammation, endothelial dysfunction, prothrombotic states, and metabolic derangements such as insulin resistance and ectopic fat deposition also play critical roles. Recent mechanistic studies highlight the interplay between chronic low-grade inflammation, immune activation, and altered lipid metabolism, culminating in ongoing vascular injury and plaque instability even in the context of optimal LDL-C control.

Risk Factors

Key contributors to residual risk include elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), increased lipoprotein(a), chronic low-grade inflammation (e.g., high-sensitivity C-reactive protein [hsCRP]), and metabolic abnormalities such as hyperglycemia and insulin resistance. Non-traditional factors—such as genetic predisposition, microalbuminuria, and markers of subclinical atherosclerosis—further modulate risk. Poor adherence to pharmacologic and lifestyle interventions, as well as social determinants of health, can also amplify residual risk.

Clinical Features

Patients at risk for cardiometabolic residual risk often present with a history of ASCVD, diabetes, or metabolic syndrome, despite apparently optimal control of conventional parameters. Clinical features may include persistent dyslipidemia (especially hypertriglyceridemia or elevated lipoprotein(a)), evidence of systemic inflammation, and progression of subclinical atherosclerotic disease detected via imaging or biomarkers. These patients frequently exhibit clustering of metabolic risk factors, with subtle clinical manifestations until overt cardiovascular events occur.

Diagnosis

Comprehensive assessment of residual risk involves evaluation of standard risk factors as well as emerging biomarkers and imaging modalities. Measurement of fasting triglycerides, HDL-C, and lipoprotein(a), along with hsCRP, can provide additional risk stratification. Coronary artery calcium scoring, carotid intima-media thickness, and other noninvasive imaging techniques can unmask subclinical atherosclerosis. Recent guidelines advocate for the use of risk-enhancing factors and advanced lipid panels to identify high-risk individuals who may benefit from intensified therapy.

Treatment & Management

Management of residual risk requires a multifaceted approach. Lifestyle modification remains foundational, emphasizing dietary optimization, regular physical activity, weight reduction, and smoking cessation. Pharmacologic strategies increasingly target non-LDL lipid fractions and inflammation. Fibrates, omega-3 fatty acids (notably icosapent ethyl), and PCSK9 inhibitors have demonstrated efficacy in selected populations. Antidiabetic agents with cardiovascular benefit, such as SGLT2 inhibitors and GLP-1 receptor agonists, offer dual metabolic and cardiovascular protection. Adjunctive therapies addressing hypertension, antithrombotic risk, and renal protection are integral components of comprehensive care.

Recent Advances / Emerging Therapies

Several novel agents and therapeutic strategies have emerged to target residual risk. PCSK9 inhibitors and inclisiran provide potent LDL-C and, to a lesser extent, Lp(a) reduction. Bempedoic acid and ANGPTL3 inhibitors are under investigation for their lipid-modifying effects. Selective anti-inflammatory therapies, such as canakinumab and colchicine, have shown promise in reducing cardiovascular events independent of lipid lowering. RNA-based therapeutics targeting Lp(a) and triglyceride metabolism represent a new frontier. Integration of genetic risk scores and machine learning approaches may further refine risk prediction and personalization of therapy.

Guideline Recommendations

Recent guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), European Society of Cardiology (ESC), and American Diabetes Association (ADA) emphasize the need for residual risk assessment and management. These guidelines recommend consideration of non-LDL risk factors, use of advanced lipid testing, and incorporation of SGLT2 inhibitors and GLP-1 receptor agonists in high-risk patients with diabetes. For those with elevated triglycerides or Lp(a), adjunctive therapies and referral to lipid specialists are advised. Shared decision-making and individualized care remain the cornerstone of guideline-based management.

Conclusion

Cardiometabolic residual risk represents a critical opportunity for further reduction of cardiovascular events in high-risk populations. Contemporary guideline perspectives underscore the importance of comprehensive risk assessment, targeted pharmacologic interventions, and the adoption of emerging therapies. Continued research, multidisciplinary collaboration, and integration of novel biomarkers and therapeutics will be essential to closing the gap in residual risk and improving long-term outcomes for patients with cardiometabolic disease.